A hospital-based bone marrow transplant programme at Qatar's national cancer centre, run by Hamad Medical Corporation, performing autologous and allogeneic blood stem cell transplants.
Hamad Medical Corporation is Qatar's main public healthcare provider, and its Bone Marrow Transplant Programme sits within the National Center for Cancer Care and Research in Doha. According to the programme's page on the corporation's website, the unit provides stem cell transplant treatment to patients aged fourteen and above. This is a hospital transplant service rather than a private regenerative medicine clinic, and the cell therapy it describes is haematopoietic (blood-forming) stem cell transplantation of the kind used in mainstream cancer and blood-disorder care.
The site states that the programme performs autologous transplants, in which a patient's own blood stem cells are collected and returned to them, and allogeneic transplants, in which the cells come from a donor. For allogeneic transplants the page describes both matched related donor transplants and haploidentical transplants, where a half-matched relative provides the cells, which it presents as an option for patients who have no fully matched donor available.
In a news item published on its own website in April 2022, Hamad Medical Corporation states that autologous stem cell transplantation was introduced at the centre in 2015 and that the allogeneic blood and marrow transplant programme was launched in 2017. The same item reports a cumulative total of 147 transplants, made up of 42 allogeneic and 105 autologous procedures, and says that 25 allogeneic and 50 autologous urgent transplants were carried out during the coronavirus pandemic. These figures are the hospital's own and have not been independently verified for this directory.
That news item also quotes the head of the programme describing the record as an outstanding achievement and saying the programme now stands alongside other stem cell transplant centres worldwide, and the corporation states that its services meet the best international standards for patient safety. Readers should treat these as the hospital's own characterisations rather than as verified findings. The pages reviewed do not promise any particular outcome for an individual patient, and this directory makes no such promise either.
The programme's page names the following groups of conditions as the ones it treats.
The site describes the service as stem cell transplantation for blood cancers and inherited blood disorders, using blood-forming stem cells either from the patient or from a related donor.
The corporation's own news page names the following clinicians in connection with the programme.
According to the programme's page, the transplant service occupies a dedicated bone marrow transplant unit of five beds fitted with specialised air filtration, a standard precaution for patients whose immune systems are suppressed after a transplant. The unit is part of the National Center for Cancer Care and Research, Qatar's national cancer hospital within Hamad Medical Corporation, in Doha. The site states that the centre has been re-accredited by Joint Commission International and that the programme is a member of the European Society for Blood and Marrow Transplantation. Care is described as being delivered by a multidisciplinary team that includes doctors, clinical pharmacists, nurses, nurse coordinators, transplant coordinators, donor advocates, nutritionists, psychologists and social workers.
The pages reviewed say nothing about what treatment costs, how it is funded or whether patients from outside Qatar are charged. Anyone wanting cost information would need to ask the hospital directly.
Profile compiled from information published on the clinic's own website and from the StemCell Registry directory record. Details may change; confirm directly with the clinic before making decisions.